Panorama Research Institute
University research centres / Academic / Research, Professional services and consulting
Non-profit organization that identifies, initiates, and incubates novel, proprietary biomedical projects that originate from in-house research or by collaboration or license from outside of PRI, offering Memantine & Derivatives, novel therapeutic antibodies, DHA-cancer drug technology, novel drugs for CV stents, somatostatin vaccine, novel CC-1065 anti-cancer drugs, novel therapeutic enzymes (TPL), KALOBIOS Taczyme technology, and NUGEN nucleic acid amplification tevchnology
No people are connected to this company
Products
Research Kits & Compounds | Panorama Research Institute
The first FDA approved drug that alters the pathogenesis of Alzheimer's disease, Mematine is an adamantane derivative shown to be an open channel blocker of the N-methyl D-aspartate (NMDA) subtype of glutamate receptors; Memantine is used for treatment of dementia and Alzheimer's disease and is likely to be useful for treatment of other conditions associated with overactivity of the NMDA receptor, such as neuropathic pain, stroke, ALS and Huntington's disease.
More information about Memantine »
